New antidiabetic drugs’ role in the management of testosterone deficiency and of the cardiovascular disease in hypogonadal diabetic men

Abstract

The known hallmarks of type 2 diabetes mellitus (T2DM), such as hyperglycemia, insulin resistance, visceral adiposity, inflammation, endothelial dysfunction, and oxidative stress, are known to influence the hypothalamus-pituitary-gonadal axis, leading to functional hypogonadism. Both the consequent testosterone (T) deficiency and diabetes are recognized factors influencing cardiovascular (CV) risk. In this context, T replacement therapy showed an improvement in glycemic control and metabolic, anthropometric, and body composition parameters in hypogonadal diabetic individuals. Observational and randomized studies on T replacement therapy suggested the beneficial effect of this treatment on CV risk, although inconclusive results should still be evaluated, particularly when subgroups of patients have to be considered. In this setting, the novel antidiabetic drugs have demonstrated beneficial effects on T levels, due to their positive effects on the hypothalamic–pituitary–gonadal axis, in addition to a proven CV protective action. Thus, the combined metabolic and CV effects of T replacement therapy and novel antidiabetic drugs are of great interest. In this review, we aimed to summarize the present state of the art concerning the association between T deficit and CV risk in diabetic people by analyzing the relationship between endogenous T and CV system in diabetic men. In particular, the impact of novel antidiabetic drugs on male hypogonadism, and the combined cardio-metabolic effects of T supplementation and novel antidiabetic drugs were discussed.

Keywords

Hypogonadism / testosterone / testosterone replacement therapy / diabetes mellitus / antidiabetic drugs / cardiovascular risk

References

[1] Dhindsa S,Batra M.Hypogonadotropic hypogonadism in men with diabesity.Diabetes Care2018;41:1516-25 PMCID:PMC6014549

[2] Maresch CC,Alves MG.Diabetes-induced hyperglycemia impairs male reproductive function: a systematic review.Hum Reprod Update2018;24:86-105

[3] Genchi VA,Lauriola C.Adipose tissue dysfunction and obesity-related male hypogonadism.Int J Mol Sci2022;23:8194 PMCID:PMC9330735

[4] Zheng R,Cao W.Risk factors for hypogonadism in male patients with type 2 diabetes.J Diabetes Res2016;2016:5162167 PMCID:PMC4781970

[5] Wang C,Swerdloff R.International Society of Andrology (ISA)International Society for the Study of Aging Male (ISSAM)European Association of Urology (EAU)European Academy of Andrology (EAA)American Society of Andrology (ASA)Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations.J Androl2009;30:1-9 PMCID:PMC2754376

[6] Santi D. ; Corona G. Primary and secondary hypogonadism. In Endocrinology of the Testis and Male Reproduction, Simoni, M., Huhtaniemi, I., Eds.Lenzi, A., Jannini, E.A., Eds.; Endocrinology; Springer; 2017. 687-747

[7] Wu FC,Beynon JM.EMAS GroupIdentification of late-onset hypogonadism in middle-aged and elderly men.N Engl J Med2010;363:123-35

[8] Bhasin S,Cunningham GR.Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline.J Clin Endocrinol Metab2018;103:1715-44

[9] Hackett G,Edwards D.British society for sexual medicine guidelines on adult testosterone deficiency, with statements for uk practice.J Sex Med2017;14:1504-23

[10] Salonia A,Boeri L.EAU Working Group on Male Sexual and Reproductive HealthEuropean association of urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction.Eur Urol2021;80:333-57

[11] Wittert G.Obesity, type 2 diabetes, and testosterone in ageing men.Rev Endocr Metab Disord2022;23:1233-42 PMCID:PMC9789005

[12] Greco C,Ebert R.Male hypogonadism and pre-diabetes interplay: association or causal interaction? a systematic review.MTOD2021;1:11

[13] Pye SR,Finn JD.EMAS Study GroupLate-onset hypogonadism and mortality in aging men.J Clin Endocrinol Metab2014;99:1357-66

[14] Andò S,Rottiers R.Androgen plasma levels in male diabetics.J Endocrinol Invest1984;7:21-4

[15] Barrett-Connor E,Yen SS.Endogenous sex hormone levels in older adult men with diabetes mellitus.Am J Epidemiol1990;132:895-901

[16] Barrett-Connor E.Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus.Ann Intern Med1992;117:807-11

[17] Chang TC,Hsiao YL.Hormonal changes in elderly men with non-insulin-dependent diabetes mellitus and the hormonal relationships to abdominal adiposity.Gerontology1994;40:260-7

[18] Defay R,Barny S,Cacès E.Hormonal status and NIDDM in the European and Melanesian populations of New Caledonia: a case-control study.Int J Obes Relat Metab Disord1998;22:927-34

[19] Goodman-Gruen D.Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women.Diabetes Care2000;23:912-8

[20] Betancourt-Albrecht M.Hypogonadism and diabetes.Int J Impot Res2003;15 Suppl 4:S14-20

[21] Tomar R,Chaudhuri A.Contrasting testosterone concentrations in type 1 and type 2 diabetes.Diabetes Care2006;29:1120-2

[22] Grossmann M,Panagiotopoulos S.Low testosterone levels are common and associated with insulin resistance in men with diabetes.J Clin Endocrinol Metab2008;93:1834-40

[23] Liu RT,Wang PW.The prevalence and predictors of androgen deficiency in Taiwanese men with type 2 diabetes.Urology2013;82:124-9

[24] Ng Tang Fui M,Cheung AS.Obesity and age as dominant correlates of low testosterone in men irrespective of diabetes status.Andrology2013;1:906-12

[25] Ho CH,Wu CC.The prevalence and the risk factors of testosterone deficiency in newly diagnosed and previously known type 2 diabetic men.J Sex Med2015;12:389-97

[26] Herrero A,Galindo P,Corrales JJ.Clinical and biochemical correlates of male hypogonadism in type 2 diabetes.Andrology2018;6:58-63

[27] Dhindsa S,Sethi M.Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes.J Clin Endocrinol Metab2004;89:5462-8

[28] Chandel A,Topiwala S,Dandona P.Testosterone concentration in young patients with diabetes.Diabetes Care2008;31:2013-7 PMCID:PMC2551646

[29] Holt SK,Hotaling J.Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research GroupPrevalence of low testosterone and predisposing risk factors in men with type 1 diabetes mellitus: findings from the DCCT/EDIC.J Clin Endocrinol Metab2014;99:E1655-60 PMCID:PMC4154094

[30] Chillarón JJ,Albareda M.TEST-DM1 Study GroupAge, insulin requirements, waist circumference, and triglycerides predict hypogonadotropic hypogonadism in patients with type 1 diabetes.J Sex Med2015;12:76-82

[31] Cai M,Yang P.Incidence and risk factors of hypogonadism in male patients with latent autoimmune diabetes and classic type 2 diabetes.Front Endocrinol2021;12:675525 PMCID:PMC8202076

[32] Ding EL,Malik VS.Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis.JAMA2006;295:1288-99

[33] Wang J,Cheskin LJ.Higher serum testosterone level was associated with a lower risk of prediabetes in US adults: findings from nationally representative data.Nutrients2022;15:9 PMCID:PMC9824532

[34] Tripathy D,Garg R.Hypogonadotropic hypogonadism in erectile dysfunction associated with type 2 diabetes mellitus: a common defect?.Metab Syndr Relat Disord2003;1:75-80

[35] Ali ST,Ashfaqsiddiqi N.Serum and urinary levels of pituitary--gonadal hormones in insulin-dependent and non-insulin-dependent diabetic males with and without neuropathy.Arch Androl1993;30:117-23

[36] Haffner SM,Mykkänen L.Insulin resistance, body fat distribution, and sex hormones in men.Diabetes1994;43:212-9

[37] Simon D,Barrett-Connor E.Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study.Diabetologia1992;35:173-7

[38] Tsai EC,Fujimoto WY.Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat.Diabetes Care2004;27:861-8

[39] Kaur H.The effect of testosterone on cardiovascular disease and cardiovascular risk factors in men: a review of clinical and preclinical data.CJC Open2021;3:1238-48 PMCID:PMC8636244

[40] Jones TH.Randomized controlled trials - mechanistic studies of testosterone and the cardiovascular system.Asian J Androl2018;20:120-30 PMCID:PMC5858094

[41] Münzer T,Sorkin JD.Growth hormone and sex steroid effects on serum glucose, insulin, and lipid concentrations in healthy older women and men.J Clin Endocrinol Metab2009;94:3833-41 PMCID:PMC2758730

[42] Sato K,Aizawa K.Testosterone and DHEA activate the glucose metabolism-related signaling pathway in skeletal muscle.Am J Physiol Endocrinol Metab2008;294:E961-8

[43] Dhindsa S,Batra M.Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes.Diabetes Care2016;39:82-91 PMCID:PMC4686848

[44] Pitteloud N,Dwyer AA.Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men.J Clin Endocrinol Metab2005;90:2636-41

[45] Paik SG,Kim YT.Induction of insulin-dependent diabetes by streptozotocin. Inhibition by estrogens and potentiation by androgens.Diabetes1982;31:724-9

[46] Palomar-Morales M,Mendoza-Rodríguez CA.The protective effect of testosterone on streptozotocin-induced apoptosis in beta cells is sex specific.Pancreas2010;39:193-200

[47] Tirabassi G,Giovannini L.Testosterone and cardiovascular risk.Intern Emerg Med2013;8 Suppl 1:S65-9

[48] Tsai EC,Leonetti DL.Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men.Int J Obes Relat Metab Disord2000;24:485-91

[49] Gupta V,Guo W.Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes.Mol Cell Endocrinol2008;296:32-40 PMCID:PMC2873614

[50] Tchernof A.Pathophysiology of human visceral obesity: an update.Physiol Rev2013;93:359-404

[51] Dieudonne MN,Boumediene A,Giudicelli Y.Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids.Am J Physiol1998;274:C1645-52

[52] Pecquery R,Cloix JF.Enhancement of the expression of the alpha 2-adrenoreceptor protein and mRNA by a direct effect of androgens in white adipocytes.Biochem Biophys Res Commun1995;206:112-8

[53] Stefan N,Birkenfeld AL,White MF.The role of hepatokines in NAFLD.Cell Metab2023;35:236-52 PMCID:PMC10157895

[54] Bourebaba N,Śmieszek A,Marycz K.Sex hormone binding globulin as a potential drug candidate for liver-related metabolic disorders treatment.Biomed Pharmacother2022;153:113261

[55] Rochira V,Genazzani AD.Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback.Eur J Endocrinol2006;155:513-22

[56] Fink J,Tamura Y.Potential application of testosterone replacement therapy as treatment for obesity and type 2 diabetes in men.Steroids2018;138:161-6

[57] Stefan N.Causes, consequences, and treatment of metabolically unhealthy fat distribution.Lancet Diabetes Endocrinol2020;8:616-27

[58] Corona G,Monami M.Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis.Eur J Endocrinol2013;168:829-43

[59] Lotti F,Maseroli E.Impact of metabolically healthy obesity in patients with andrological problems.J Sex Med2019;16:821-32

[60] Cohen PG.The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity.Med Hypotheses1999;52:49-51

[61] Finn PD,Pau KY.The stimulatory effect of leptin on the neuroendocrine reproductive axis of the monkey.Endocrinology1998;139:4652-62

[62] Majumdar S,Ray S.Testosterone replacement therapy in men with type 2 diabetes mellitus and functional hypogonadism -an integrated diabetes and endocrine academy (IDEA) consensus guideline.Diabetes Metab Syndr2021;15:102191

[63] Blouin K,Luu-The V.Androgen metabolism in adipose tissue: recent advances.Mol Cell Endocrinol2009;301:97-103

[64] Soisson V,Helmer C.A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study.Maturitas2013;75:282-8

[65] Laughlin GA,Bergstrom J.Low serum testosterone and mortality in older men.J Clin Endocrinol Metab2008;93:68-75 PMCID:PMC2190742

[66] Shores MM,Sloan KL.Low serum testosterone and mortality in male veterans.Arch Intern Med2006;166:1660-5

[67] Khaw KT,Folkerd E.Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study.Circulation2007;116:2694-701

[68] Corona G,Di Pasquale G.Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies.J Sex Med2018;15:1260-71

[69] Muraleedharan V,Kapoor D,Jones TH.Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes.Eur J Endocrinol2013;169:725-33

[70] Vignozzi L,Cellai I.Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation.Prostate2013;73:789-800

[71] Vignozzi L,Corona G.Benign prostatic hyperplasia: a new metabolic disease?.J Endocrinol Invest2014;37:313-22

[72] Morelli A,Comeglio P.Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits.Mol Cell Endocrinol2014;382:107-19

[73] Vignozzi L,Comeglio P.Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.Mol Cell Endocrinol2014;384:143-54

[74] Rosano GM,Fini M.Testosterone in men with hypogonadism and high cardiovascular risk, pros.Endocrine2015;50:320-5

[75] Keating NL,Smith MR.Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.J Clin Oncol2006;24:4448-56

[76] D'Amico AV,Crook J.Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.J Clin Oncol2007;25:2420-5

[77] Saigal CS,Krupski TL,Schonlau M.Urologic Diseases in America ProjectAndrogen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.Cancer2007;110:1493-500

[78] Tsai HK,Sadetsky N,Carroll PR.Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.J Natl Cancer Inst2007;99:1516-24

[79] Haque R,Xu X.Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.Br J Cancer2017;117:1233-40 PMCID:PMC5674100

[80] Corona G G,Maseroli E,Maggi M.Testosterone replacement therapy and cardiovascular risk: a review.World J Mens Health2015;33:130-42 PMCID:PMC4709429

[81] Isidori AM,Gianfrilli D.Effects of testosterone on sexual function in men: results of a meta-analysis.Clin Endocrinol2005;63:381-94

[82] Isidori AM,Greco EA.Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis.Clin Endocrinol2005;63:280-93

[83] Snyder PJ,Berlin JA.Effects of testosterone replacement in hypogonadal men.J Clin Endocrinol Metab2000;85:2670-7

[84] Sih R,Kaiser FE.Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.J Clin Endocrinol Metab1997;82:1661-7

[85] Jones TH,Behre HM.TIMES2 InvestigatorsTestosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).Diabetes Care2011;34:828-37

[86] Jones TH.The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process.Atherosclerosis2009;207:318-27

[87] Spitzer M,Basaria S,Bhasin S.Risks and benefits of testosterone therapy in older men.Nat Rev Endocrinol2013;9:414-24

[88] Basaria S,Travison TG.Adverse events associated with testosterone administration.N Engl J Med2010;363:109-22

[89] Finkle WD,Ridgeway GK.Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men.PLoS One2014;9:e85805 PMCID:PMC3905977

[90] Vigen R,Barón AE.Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.JAMA2013;310:1829-36

[91] Corona G,Guaraldi F.An update on heart disease risk associated with testosterone boosting medications.Expert Opin Drug Saf2019;18:321-32

[92] Pugh PJ,Channer KS.Acute haemodynamic effects of testosterone in men with chronic heart failure.Eur Heart J2003;24:909-15

[93] Malkin CJ,West JN,Jones TH.Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial.Eur Heart J2006;27:57-64

[94] Caminiti G,Iellamo F.Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study.J Am Coll Cardiol2009;54:919-27

[95] Traish AM,Haider KS,Saad F.Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (Control) groups.J Cardiovasc Pharmacol Ther2017;22:414-33 PMCID:PMC5555449

[96] Bhasin S,Basaria S.TRAVERSE Study InvestigatorsEffects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study.Am Heart J2022;245:41-50

[97] Dandona P,Ghanim H.Mechanisms underlying the metabolic actions of testosterone in humans: a narrative review.Diabetes Obes Metab2021;23:18-28

[98] Haider KS,Saad F.Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study.Diabetes Obes Metab2020;22:2055-68 PMCID:PMC7689919

[99] Wittert G,Robledo KP.Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial.Lancet Diabetes Endocrinol2021;9:32-45

[100] Caliber M.Testosterone therapy for prevention and reversal of type 2 diabetes in men with low testosterone.Curr Opin Pharmacol2021;58:83-9

[101] Kumar S,Memon RA.Effects of testosterone therapy in adult males with hypogonadism and T2DM: a meta-analysis and systematic review.Diabetes Metab Syndr2022;16:102588

[102] Janjgava S,Uchava L,Asatiani K.Influence of testosterone replacement therapy on metabolic disorders in male patients with type 2 diabetes mellitus and androgen deficiency.Eur J Med Res2014;19:56 PMCID:PMC4213476

[103] Jeong SM,Park MG.Effect of testosterone replacement treatment in testosterone deficiency syndrome patients with metabolic syndrome.Korean J Urol2011;52:566-71 PMCID:PMC3162224

[104] Ghanim H,Batra M.Testosterone increases the expression and phosphorylation of amp kinase α in men with hypogonadism and type 2 diabetes.J Clin Endocrinol Metab2020;105:1169-75 PMCID:PMC7077952

[105] Mårin P,Gustafsson C.Androgen treatment of abdominally obese men.Obes Res1993;1:245-51

[106] Hackett G.Metabolic effects of testosterone therapy in men with type 2 diabetes and metabolic syndrome.Sex Med Rev2019;7:476-90

[107] Hackett G,Bhartia M,Raju J.BLAST Study GroupTestosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study.J Sex Med2014;11:840-56

[108] Krysiak R,Okopień B.The effect of testosterone on cardiovascular risk factors in men with type 2 diabetes and late-onset hypogonadism treated with metformin or glimepiride.Pharmacol Rep2016;68:75-9

[109] Groti K,Antonič B,Pfeifer M.The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes.Aging Male2018;21:158-69

[110] Khripun I,Belousov I,Zitzmann M.Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial.Aging Male2019;22:241-9

[111] Farias JM,Khoury M.Low testosterone concentration and atherosclerotic disease markers in male patients with type 2 diabetes.J Clin Endocrinol Metab2014;99:4698-703 PMCID:PMC4255118

[112] Daka B,Larsson CA.Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus.BMC Endocr Disord2015;15:35 PMCID:PMC4514972

[113] Muraleedharan V.Testosterone and mortality.Clin Endocrinol2014;81:477-87

[114] Lv Z.Metformin and its benefits for various diseases.Front Endocrinol2020;11:191 PMCID:PMC7212476

[115] Rosenstock J,González-Ortiz M.Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes.Diabetes Care2016;39:353-62

[116] Søfteland E,Vangen B.Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial.Diabetes Care2017;40:201-9

[117] Faure M,Alves S.The insulin sensitiser metformin regulates chicken Sertoli and germ cell populations.Reproduction2016;151:527-38

[118] Tartarin P,Guibert E.Metformin exposure affects human and mouse fetal testicular cells.Hum Reprod2012;27:3304-14

[119] Hu Y,Shen Y.Rapid Changes in Serum Testosterone in men with newly diagnosed type 2 diabetes with intensive insulin and metformin.Diabetes Care2021;44:1059-61 PMCID:PMC7985426

[120] Cai T,Ding B.Effect of metformin on testosterone levels in male patients with type 2 diabetes mellitus treated with insulin.Front Endocrinol2021;12:813067 PMCID:PMC8740051

[121] Martin Martins J,Martins Maia C.Primary and secondary hypogonadism in male persons with diabetes mellitus.Int J Endocrinol2021;2021:8799537 PMCID:PMC8197670

[122] Wensink MJ,Tian L.Preconception antidiabetic drugs in men and birth defects in offspring : a nationwide cohort study.Ann Intern Med2022;175:665-73 PMCID:PMC9844982

[123] Caruso I,Laviola L.GLP-1 receptor agonists for cardiovascular protection: a matter of time.Diabetes Care2022;45:e30-1 PMCID:PMC8914435

[124] Wadden TA,Klein S.NN8022-1923 InvestigatorsWeight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.Int J Obes2013;37:1443-51

[125] Davies MJ,Bode B.NN8022-1922 Study GroupEfficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial.JAMA2015;314:687-99

[126] Brown E,Cuthbertson DJ.SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.Lancet2021;398:262-76

[127] Caruso I,Giorgino F.Heterogeneity and similarities in GLP-1 receptor agonist cardiovascular outcomes trials.Trends Endocrinol Metab2019;30:578-89

[128] Caruso I.SGLT-2 inhibitors as cardio-renal protective agents.Metabolism2022;127:154937

[129] Caruso I,Laviola L.Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?.Diabetes Obes Metab2021;23:2194-6

[130] Zou CY,Sang YQ,Liang J.Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis.Medicine2019;98:e18245 PMCID:PMC6919451

[131] Johansen ME.The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.Clin Cardiol2020;43:1376-87 PMCID:PMC7724239

[132] Cignarelli A,D'Oria R.Role of glucose-lowering medications in erectile dysfunction.J Clin Med2021;10:2501 PMCID:PMC8201035

[133] Sansone A,Cignarelli A.Effect of treatment with testosterone on endothelial function in hypogonadal men: a systematic review and meta-analysis.Int J Impot Res2020;32:379-86

[134] Efesoy O,Akbay E.The effect of testosterone replacement therapy on penile hemodynamics in hypogonadal men with erectile dysfunction, having veno-occlusive dysfunction.Am J Mens Health2018;12:634-8 PMCID:PMC5987956

[135] Morgentaler A,Caliber M,Khera M.Testosterone therapy and cardiovascular risk: advances and controversies.Mayo Clin Proc2015;90:224-51

[136] Morgentaler A,Traish AM.Fundamental concepts regarding testosterone deficiency and treatment: international expert consensus resolutions.Mayo Clin Proc2016;91:881-96

[137] Wallis CJ,Lee Y.Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study.Lancet Diabetes Endocrinol2016;4:498-506

[138] MacLusky NJ,Scrocchi L.Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling.Endocrinology2000;141:752-62

[139] Caltabiano R,Panza S.Glucagon-like peptide-1 receptor is expressed in human and rodent testis.Andrology2020;8:1935-45

[140] Beak SA,Small CJ.Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line.J Clin Invest1998;101:1334-41 PMCID:PMC508688

[141] Oride A,Mijiddorj T.GLP-1 increases Kiss-1 mRNA expression in kisspeptin-expressing neuronal cells.Biol Reprod2017;97:240-8

[142] Abdullah DM,Khamis T.Semaglutide early intervention attenuated testicular dysfunction by targeting the GLP-1-PPAR-α-Kisspeptin-Steroidogenesis signaling pathway in a testicular ischemia-reperfusion rat model.Peptides2022;149:170711

[143] Zhang E,Liang H.GLP-1 receptor agonist exenatide attenuates the detrimental effects of obesity on inflammatory profile in testis and sperm quality in mice.Am J Reprod Immunol2015;74:457-66

[144] Martins AD,Silva BM.Metabolic dynamics of human Sertoli cells are differentially modulated by physiological and pharmacological concentrations of GLP-1.Toxicol Appl Pharmacol2019;362:1-8

[145] Rago V,Santoro M.Human sperm express the receptor for glucagon-like peptide-1 (GLP-1), which affects sperm function and metabolism.Endocrinology2020;161:bqaa031

[146] Marso SP,Brown-Frandsen K.LEADER Steering CommitteeLEADER Trial InvestigatorsLiraglutide and cardiovascular outcomes in type 2 diabetes.N Engl J Med2016;375:311-22 PMCID:PMC4985288

[147] Gerstein HC,Dagenais GR.REWIND InvestigatorsDulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.Lancet2019;394:121-30

[148] Marso SP,Consoli A.SUSTAIN-6 InvestigatorsSemaglutide and cardiovascular outcomes in patients with type 2 diabetes.N Engl J Med2016;375:1834-44

[149] Holman RR,George J.Rationale and design of the EXenatide study of cardiovascular event lowering (EXSCEL) trial.Am Heart J2016;174:103-10

[150] Holman RR,Mentz RJ.EXSCEL Study GroupEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.N Engl J Med2017;377:1228-39 PMCID:PMC9792409

[151] Bethel MA,Merrill P.EXSCEL Study GroupCardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.Lancet Diabetes Endocrinol2018;6:105-13

[152] Sudo M,Hiro T.Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits.Atherosclerosis2017;265:283-91

[153] Yuan P,Gao X.Liraglutide ameliorates erectile dysfunction via regulating oxidative stress, the RhoA/ROCK pathway and autophagy in diabetes mellitus.Front Pharmacol2020;11:1257 PMCID:PMC7435068

[154] Giagulli VA,Ramunni MI.Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.Andrology2015;3:1094-103

[155] Bajaj HS,Rao-Melacini P.Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.Lancet Diabetes Endocrinol2021;9:484-90

[156] Shao N,Yu YM.Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity.Andrologia2018;50:e13039

[157] Jensterle M,Goricar K,Janez A.Effects of liraglutide on obesity-associated functional hypogonadism in men.Endocr Connect2019;8:195-202 PMCID:PMC6391904

[158] Giagulli VA,Carbone MD.Weight loss more than glycemic control may improve testosterone in obese type 2 diabetes mellitus men with hypogonadism.Andrology2020;8:654-62

[159] Graybill S,Kravchenko M.Neutral effect of exenatide on serum testosterone in men with type 2 diabetes mellitus: a prospective cohort.Andrology2021;9:792-800

[160] Jeibmann A,Simoni M,Byrne MM.Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males.Eur J Clin Invest2005;35:565-72

[161] Lee DM,Jarrell DK.SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.Cardiovasc Diabetol2018;17:62 PMCID:PMC5921754

[162] Park SH,Gaertner S.Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.Cardiovasc Diabetol2020;19:19 PMCID:PMC7026972

[163] Solini A,Seghieri M.Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.Cardiovasc Diabetol2017;16:138 PMCID:PMC5654086

[164] Assaly R,Compagnie S.The favorable effect of empagliflozin on erectile function in an experimental model of type 2 diabetes.J Sex Med2018;15:1224-34

[165] Luo ZC,Jiang YF.The protective effects and underlying mechanisms of dapagliflozin on diabetes-induced testicular dysfunction.Asian J Androl2023;25:331-8 PMCID:PMC10226494

[166] Araujo AB,Suarez EA,Guey LT.Endogenous testosterone and mortality in men: a systematic review and meta-analysis.J Clin Endocrinol Metab2011;96:3007-19 PMCID:PMC3200249

[167] Gagliano-Jucá T.Testosterone replacement therapy and cardiovascular risk.Nat Rev Cardiol2019;16:555-74

[168] Malipatil NS,Lunt M.Male hypogonadism: 14-year prospective outcome in 550 men with type 2 diabetes.Endocrinol Diabetes Metab2019;2:e00064 PMCID:PMC6613223

[169] Yao QM,An XF,Ding L.Testosterone level and risk of type 2 diabetes in men: a systematic review and meta-analysis.Endocr Connect2018;7:220-31 PMCID:PMC5793809

[170] Kapoor D,Channer KS.Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.Eur J Endocrinol2006;154:899-906

[171] Gianatti EJ,Hoermann R.Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial.Diabetes Care2014;37:2098-107

[172] Antonič K, Antonič B, Žuran I, Pfeifer M. Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial).Aging Male2020;23:1442-54